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ABSTRACT
Introduction: Randomized clinical trials
showed that vildagliptin is well tolerated and
leads to clinically meaningful decreases in gly-
cated hemoglobin (HbA1c) and fasting plasma
glucose (FPG) both in monotherapy and as add-
on therapy in inadequately controlled type 2
diabetes mellitus (T2DM) patients. Nevertheless,
there is an increased interest for real-life studies
to confirm the clinical trial findings in the set-
ting of a daily clinical practice. The aim of this
study was to evaluate the effectiveness and tol-
erability of vildagliptin in a real-life clinical set-
ting and to explore factors determining drug
adherence and T2DM management.
Methods: G-FORCE was a prospective, obser-
vational, open-label, multi-center study in
which T2DM patients were prescribed de novo
vildagliptin. Clinical effectiveness was deter-
mined by changes in HbA1c and FPG and by the
proportion of patients reaching glycemic goal.
Data were collected at baseline, after 105 ±
15 days and after 180 ± 15 days.
Results: A total of 1230 patients were included
in this analysis. Mean age was 63.9 ± 10.8 years,
and mean HbA1c and FPG levels were 8.2 ±
1.3% and 171.0 ± 53.3 mg/dL, respectively. At
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180 days of treatment, HbA1c and FPG levels
decreased to 7.2 ± 1.0% and 141.1 ± 44.0 mg/
dL, respectively, while the proportion of
patients reaching HbA1c and FPG goals rose
from 8.6 to 44.6% and from 14.2 to 42.8%,
respectively.
Conclusion: In this real-world study, vildaglip-
tin was an effective and safe treatment for
T2DM patients already treated with metformin,
while the single pill combination of vildagliptin
and metformin provides a convenient alterna-
tive while ensuring comparable effectiveness
and tolerability.
Funding: Novartis Pharma.
Keywords: DPP4i; HbA1c; Real-world; T2DM;
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ALT Alanine aminotransferase
AST Aspartate aminotransferase
FPG Fasting plasma glucose
GLP-1 Glucagon-like peptide-1
Hba1c Glycated hemoglobin
HDL High-density lipoprotein
LDL Low-density lipoprotein
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic
and progressive disease. Only 50% of individu-
als with T2DM achieve glycemic control defined
by a glycated hemoglobin (HbA1c) target of
\ 7%. This hyperglycemia, if left insufficiently
treated, can cause damage to various body
organs, leading to life-threatening complica-
tions, such as cardiovascular disease, neuropa-
thy, nephropathy and retinopathy [1]. Whereas
type 1 diabetes mellitus (T1DM) is characterized
by an auto-immune response that in turn is
characterized by insulin deficiency due to pan-
creatic beta cell loss [2], T2DM is caused by
progressively impaired insulin secretion by
pancreatic beta cells, usually upon a back-
ground of pre-existing insulin resistance in
skeletal muscle, liver and adipose tissue [3].
T2DM is far more common (accounting for
[ 90% of all DM cases) than either T1DM or
gestational diabetes. In 2017, an estimated 425
million people worldwide were living with
T2DM, and this figure is projected to rise to 629
million by 2045 [1].
According to a consensus report by the
American Diabetes Association (ADA) and the
European Association for the Study of Diabetes
(EASD), the goals of treatment for T2DM are to
prevent or delay complications and to maintain
quality of life. This therapeutic strategy requires
control of glycemia and cardiovascular risk fac-
tor management, regular follow-up and,
importantly, a patient-centered approach to
enhance patient engagement in self-care activ-
ities. Although preserving and enhancing beta
cell function is perceived as the holy grail of
diabetes treatment, effective techniques are still
inadequately developed [4]. Several landmark
trials clearly showed that lower HbA1c levels are
associated with reduced onset or progression of
a number of microvascular complications [5, 6].
A reasonable glycemic goal recommended by
both the ADA and EASD for many adults is a
HbA1c level of \ 7%, but numerous aspects
must be considered when setting glycemic tar-
gets, and each target must be individualized to
the needs of each patient and his or her disease
factors. Lifestyle interventions, including med-
ical nutrition therapy and physical activity, are
effective and safe treatment options for
improving glucose control in individuals with
T2DM. For these reasons, they are recom-
mended as first-line therapies from the time of
diagnosis and as cotherapy for patients who also
require glucose-lowering medications. Lifestyle
management should be part of the ongoing
discussion with individuals with T2DM at each
visit [4]. Ultimately, most patients will require
pharmacotherapy with multiple agents to
achieve successful glycemic control [7].
Currently, there are nine major classes of
glucose-lowering drugs approved for clinical use
in Belgium of which six drugs, i.e. metformin,
sulphonylurea, glinides, glitazones, dipeptidyl
peptidase-4 inhibitors (DPP-4i) and sodium
glucose co-transporter two inhibitors (SGLT2i)
are oral glucose-lowering agents with different
mechanisms of action. Metformin, if not con-
traindicated and if tolerated, is the preferred
initial pharmacologic agent for the treatment of
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T2DM, while a patient-centered approach
should be used to guide the choice of additional
pharmacologic agents [8].
Vildagliptin is a potent selective inhibitor of
the enzyme dipeptidyl peptidase-4 (DPP-4),
which is responsible for the rapid degradation
of circulating glucagon-like peptide-1 and glu-
cose-dependent insulinotropic peptide [9].
Mechanistic studies have shown that vildaglip-
tin improves islet function in patients with
T2DM by increasing both alpha and beta cell
responsiveness to glucose [10, 11]. The clinical
efficacy of vildagliptin in reducing HbA1c is
well established [12–17], and the safety and
tolerability profile has been shown to be excel-
lent compared to sulfonylurea or thiazolidine-
dione therapy [14, 16].
Most of the studies demonstrating the effi-
cacy and effectiveness of vildagliptin in patients
with T2DM are randomized controlled trials.
While metformin is still the most prescribed
glucose-lowering agent, the use of DDP-4i as a
second-line treatment has strongly increased
over the years, while the use of sulphonylureas
and glitazones has decreased [18–21]. Never-
theless, data on the effectiveness of managing
hyperglycemia in T2DM with vildagliptin with
or without metformin is limited in clinical
practice. Further, managing T2DM with subse-
quent switch to the single pill combination
(SPC) vildagliptin/metformin is not fully
understood in terms of clinical outcomes and
associated patient- and clinician-level determi-
nants. The G-FORCE study was conducted to
gain a better understanding of the real value of
treatment with the DPP-4i vildagliptin. The
objective of this study was to evaluate the
effectiveness and tolerability of vildagliptin in a
real-life clinical setting and to explore patient-
and physician determinants of glycemic
outcomes.
METHODS
Study Design
G-FORCE was a prospective, observational,
open-label, single-arm, multi-center study of
practice patterns, lifestyle behaviors and clinical
outcomes in patients with T2DM for whom the
treating physician, per best clinical judgment,
decided to prescribe de novo vildagliptin at
baseline (visit 1). Per the inclusion criteria, all
patients had been treated with metformin, with
or without other agents, prior to enrollment.
The study included three time points: baseline
(visit 1), 105 ± 15 days (visit 2) and
180 ± 15 days (visit 3). In accordance with local
regulations, patients could be switched to the
SPC vildagliptin/metformin after 3 months.
The study was approved by the Medical
Ethical Committee of Antwerp University
Hospital (Belgium). All procedures performed in
studies involving human participants were in
accordance with the ethical standards of the
Antwerp University Hospital (Belgium) and
with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards.
All subjects (or their legal guardian) gave writ-
ten informed consent before participating in
the study. Participation in this study did not
affect individual treatment according to medi-
cal needs of the patients. The procedures and
decisions of the physicians were not influenced
and there were no required tests or other
assessments to be done other than those per-
formed in routine clinical practice.
Study Population
A total of 1480 patients were enrolled in 314
primary care practices. Eligible participants were
patients diagnosed with T2DM who had been
treated with metformin, with or without other
agents, prior to enrollment. The T2DM of all
patients was considered to be inadequately
controlled by this therapy by the treating
physician. Consequently, the physician decided
upon a therapy with vildagliptin as add-on to
metformin or a switch to the SPC of metformin
and vildagliptin after 3 months of treatment
with both mono-components, according to the
local reimbursement criteria. As this was an
observational study, all data recorded were
available from routine clinical practice. Exclu-
ded from the study were patients with prior
vildagliptin or vildagliptin/metformin treat-
ment, patients requiring insulin therapy and
Diabetes Ther (2019) 10:965–979 967
patients exposed to any investigational agent in
the 30 days prior to enrollment. The evaluable
sample included only those patients for whom
at least one HbA1c level was recorded at either
visit 2 or visit 3.
The study duration was 180 days, and the
patients were evaluated three times: baseline
(visit 1) and after approximately 105 ± 15 days
(visit 2) and 180 ± 15 days (visit 3). The fol-
lowing patient data were collected at entry into
the study: socio-demographic data, relevant
physical examination data, medical history
data, history of present disease, comorbidities,
risk factors, lifestyle behaviors, diabetes medi-
cations and concomitant medications. Baseline
physician data, including socio-demographic
data, medical education and specialization,
practice environment (including patient mix
and volume), knowledge of best practice
guidelines and use of evidence-based practice
guidelines, were also collected. For the data in
the guidelines, questionnaires used in hyper-
tension studies were adapted to the diabetes
context [22].
The primary effectiveness outcomes were
HbA1c level, goal achievement of HbA1c\7%,
fasting plasma glucose (FPG) level and goal
achievement of FPG \ 126 mg/dL. Secondary
outcomes of interest were body mass index
(BMI); waist circumference; levels of total
cholesterol, low- (LDL) and high-density (HDL)
lipoprotein cholesterol and triglycerides; blood
pressure; and alanine (ALT) and aspartate
aminotransferase (AST) levels. Blood pressure
was measured with the individual in a sitting
position, with the arm supported at heart level,
and using an appropriately sized cuff for a total
of three times, starting at least 5 min after the
start of each visit and repeated at 2- to 3-min
intervals. The mean of the three measurements
was recorded without rounding off. All of these
parameters were measured at all three visits. All
laboratory data were collected as available in
routine clinical practice, and no central labora-
tory was used.
Changes in glucose-lowering therapy and
the occurrence of adverse events (AE) and seri-
ous adverse events (SAE) were also documented.
At visits 2 and 3, patients were asked to provide
details of any such events experienced since the
prior visit.
Medication Adherence
A modification of the Basel Assessment of
Adherence Scale [23] was used to query patients
about their medication adherence in the
4 weeks preceding each study time point. These
queries focused on: (1) having not taken medi-
cation; (2) having skipped several doses or taken
dose(s) C 2 hours off schedule. Each of these
queries were scored in terms of frequency
(0 = adherent to 5 = non-adherent) and then
averaged to yield a composite adherence score
of 0–5. Additionally, a single-item visual analog
scale (VAS; 10 cm, converted to 0–100%) was
used to collect physicians’ perception of each
patient’s adherence to their glucose-lowering
medication (on a 0–100% scale); and a VAS was
also used to record patients’ self-reported
adherence to their glucose-lowering
medication.
Statistical Analysis
All data were analyzed using SAS version 9.1
software (SAS Institute, Cary, NC, USA). Statis-
tical significance was set at p\ 0.05. Descriptive
statistics of frequency, central tendency and
dispersion were used to describe the variables of
interest being considered at the applicable
levels of measurement. As described previously
[22], each participating physician recruited
several patients, and therefore patients could
not be considered independent but instead
‘nested’ under their treating physician. A linear
mixed model for normally distributed data and
logistic regression with generalized estimation
equations for other data, such as dichotomous/
ordinal control rates, were applied.
RESULTS
Patients
The flow of patients in the study is shown in
Fig. 1. Of the 1587 patients initially screened,
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1480 gave written informed consent, of which
1294 completed the study. For 64 patients, no
HbA1c measurement was available for at least
one of the two follow-up visits. Thus, the
evaluable sample consisted of 1230 patients
contributed by 314 physician-investigators.
The clinical baseline characteristics of the
patients prior to the initiation of vildagliptin
are given in Table 1. The mean age of the
patients was 63.9 ± 10.8 years; 45.1% of the
patients were aged C 65 years and 58.1% were
male. Mean BMI was 30.2 ± 5.6 kg/m2, mean
body weight was 87.0 ± 17.0 kg and mean waist
circumference was 106.9 ± 16.8 cm. The mean
time since diagnosis of T2DM was
6.6 ± 5.8 years, and at the time of enrollment
mean HbA1c and FPG were 8.2 ± 1.3% and
171.0 ± 53.3 mg/dL, respectively. LDL, HDL
and triglycerides levels were 107.0 ± 38.2,
50.4 ± 18.8 and 180.6 ± 93.8 mg/dL, respec-
tively. ALT and AST levels were 29.3 ± 20.3 and
34.4 ± 27.6 U/L respectively, whereas mean
systolic and diastolic blood pressure were
135.2 ± 12.8 and 80.7 ± 8.4 mmHg, respec-
tively. Many patients were diagnosed with
comorbidities, of which the most prevalent
were dyslipidemia (71.9%); cardiac pathology
(23.2%), defined as myocardial infraction, heart
failure, revascularization, etc.; renal pathology
(14.1%), defined as micro-albuminuria or ele-
vated creatinine; peripheral artery disease
(12.3%); and psychiatric disorder (12.3%). The
majority of patients had cardio-metabolic risk
factors, such as lack of exercise (72.4%),
abdominal obesity, based on physician’s judge-
ment (71.4%), persistent high carbohydrate
intake despite the diabetes diagnosis (56.6%), a
family history of diabetes (39.1%) and to a lesser
extent, smoking (18.3%) and excessive alcohol
intake (16.3%).
Physician-Investigators
The majority of the 314 physician-investigators
were male (81.0%) and practicing solo (79.3%)
to a mixed population of patients of all ages
(82.0%). They were on average 50.9 ± 9.4 years
old and had been practicing medicine for
25.5 ± 10.0 years. The median number of
T2DM patients seen in the past year was 70, of
Fig. 1 Flowchart of patient recruitment and disposition. HbA1c Glycated hemoglobin
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whom a median of 30% had uncontrolled
HbA1c (defined as having a HbA1c of [ 7%).
The median time spent on a first visit with a
newly diagnosed T2DM patient was 20 min,
whereas the median time spent on a visit for a
diagnosed patient was 15 min. Physicians ten-
ded to initiate treatment at a median FPG of
126 mg/dL and a median HbA1c of 7% using
primarily one or two oral agents. Most of them
considered a family history of T2DM (82.5%),
obesity (80.9%), dyslipidemia (75.5%) and
Table 1 Patient demographics and clinical status
Patient demographics and clinical status Values
Demographics
Gender (%)
Male 58.1
Female 41.9
Age (mean ± SD) (years) 63.9 ± 10.8
\ 65 54.9%
C 65 45.1%
Body weight (kg) 87.0 ± 17.0
Body mass index (km/m2) (mean ± SD) 30.2 ± 5.6
Waist circumference (cm) (mean ± SD) 106.9 ± 16.7
Time since diagnosis (mean ± SD) (years) 6.6 ± 5.8
Prior glucose-lowering agents
(in addition to metformin) (% of patients)
Sulfonylurea 32.8
Repaglinide 13.7
Glitazones 16.1
GLP-1 analog 0.3
Clinical status at enrollment (mean – SD)
Glycemia
HbA1c (%) 8.2 ± 1.3
FPG (mg/dL) 171.0 ± 53.3
Lipids (mg/dL)
Total cholesterol 193.0 ± 44.4
LDL 107.0 ± 38.2
HDL 50.4 ± 18.8
Triglycerides 180.6 ± 93.8
Liver enzymes (U/L)
AST 29.3 ± 20.3
ALT 34.4 ± 27.6
Blood pressure (mmHg)
Systolic 135.2 ± 12.8
Diastolic 80.7 ± 8.4
Table 1 continued
Patient demographics and clinical status Values
Comorbidities (% of patients)a
Dyslipidemia 71.9
Cardiac pathology 23.2
Renal pathology 14.1
Peripheral artery disease 12.3
Psychiatric disorder 12.3
Neuropathy 11.8
Cerebrovascular pathology 10.6
Diabetic eye disease 6.2
Skin ulceration 5.2
Amputation 1.0
Risk factors (% of patients)a
Lack of regular exercise 72.4
Obesity 71.4
Persistent high carbohydrate intake 56.6
Family history of diabetes 39.1
Active smoker 18.3
Excessive alcohol intake 16.3
ALT Alanine aminotransferase, AST aspartate amino-
transferase, FPG Fasting plasma glucose, GLP-1 glucagon-
like peptide-1, HbA1c glycated hemoglobin, HDL high-
density lipoprotein cholesterol, LDL low-density lipopro-
tein cholesterol, SD standard deviation
a Categories are not mutually exclusive. Patients may have
had more than one condition. Percentage was calculated
on number of valid reports
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hypertension (69.1%) as important factors
influencing the decision to screen patients for
T2DM. HbA1c level was considered to be the
most important factor in the management of
T2DM by the majority of physicians (54.5%),
followed by fasting glycemia (12.4%). The fol-
lowing patient comorbidities were considered
by the physicians as leading to a more aggres-
sive glycemic control: hypertension (87.0%),
previous cardiovascular event (82.8%), renal
disease (81.2%), retinopathy by diabetes
(78.0%) and hyperlipidemia (71.7%). Of the
participating physicians, 38.9 and 33.4% discuss
T2DM and its complications with the patient at
least every 2 or 6 months, respectively, whereas
42.0 and 33.1% of them discuss the glucose-
lowering medication with their patient at least
every 2 or 6 months, respectively. Almost one-
quarter (23.9%) of the physicians had never
heard of the EASD guidelines, and 6.4% stated
not being interested in these guidelines. Only
18.5% reported to know and use the EASD
guidelines in their clinical practice.
Glucose-Lowering Treatment Patterns
Per the inclusion criteria, all patients had been
treated with metformin, with or without other
agents, prior to enrollment. On average,
patients’ glucose-lowering medication had been
changed 2.5 ± 1.6 times, and patients had been
on 1.9 ± 0.8 different agents before treatment
with vildagliptin was initiated. As shown in
Table 2, most patients were started on vilda-
gliptin in combination with metformin
(92.9%), but some (7.1%) were started on vil-
dagliptin only. At the time of enrollment, the
most used concomitant glucose-lowering med-
ications were glitazones and sulphonylurea
(16.1 and 12.1%, respectively, of the patients).
Among antihypertensive agents prescribed,
57.7% of patients were prescribed either an
angiotensin receptor blocker or an angiotensin
converting enzyme inhibitor, whereas beta-
blockers were prescribed in 31.0% of the
patients. Consistent with the cardio-metabolic
risk profile, 68.0% of patients were on statin
therapy, while about one-half of patients
(51.1%) were prescribed low-dose aspirin.
At visit 2, 22.7% of patients were switched to
the SPC vildagliptin/metformin; a similar rate
(22.1%) was observed at visit 3. As a result, the
proportions of patients on the free regimen of
vildagliptin and metformin therapy decreased
to about two-thirds of patients at visit 2 (69.1%)
and visit 3 (64.4%). The use of concomitant
glucose-lowering medications remained con-
stant with the exception of the class of glita-
zones: as a result of the initiation of
vildagliptin, ± 13% of the patients were taken
off glitazones, so the percentage of patients
treated with glitazones decreased from 16.1% at
baseline to 2.4 and 2.8% at visit 2 and 3,
respectively.
Non-Adherence
When asked about their medication behavior in
the preceding 4 weeks, the proportion of
patients giving answers indicative of non-ad-
herence decreased from baseline to visit 2 and 3
for all three adherence behaviors of interest, i.e.
not having taken medication, skipping several
doses and taking medication more than 2 h off
schedule (all p\0.01), as well as for the mean
composite of frequency of non-adherence
(p\ 0.0001) (Table 2). Mean patient and
physician VAS ratings of adherence increased by
3.1 and 5.3%, respectively, from baseline to visit
3 (p\0.0001), and the VAS ratings of patient
and physician were correlated highly at each of
the three visits (all p\ 0.0001). The most
important reasons for patients’ poor adherence
were forgetfulness of prescriptions (33.4%), lack
of understanding of the importance of long-
term continuing treatment (21.3%) and refusal
to accept the chronic nature of the disease
(14.0%). Suggestions given by the physicians to
improve patient adherence were dosage simpli-
fication (31.5%) and provision of information
to the patient (29.3%).
Clinical Outcomes
Effectiveness of vildagliptin was analyzed based
on 1230 patients whose HbA1c levels could be
obtained for all three time points of the study
(at baseline and at visits 2 and 3). At initiation
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Table 2 Treatment patterns and patient adherence at each time point
Treatment patterns and patient adherence Study time points
Baseline 105 – 15 days 180 – 15 days
Treatments (% of patients)
Vildagliptin only (monotherapy) 7.1 6.2 10.5
Vildagliptin ? metformin 92.9 69.1 64.4
SPC vildagliptin/metformin – 22.7 22.1
No treatment – 2.0 3.0
Concomitant glucose-lowering agents (% of patients)
Sulfonylurea 12.1 12.0 11.2
Repaglinide 7.6 7.1 6.6
Glitazones 16.1 2.4 2.8
GLP-1 analog 1.5 1.5 1.4
Other concomitant medications (at baseline) (% of patients)
Blood pressure-lowering agents (% of patients)
Beta-blocker 31.0
Angiotensin converting enzyme inhibitor 28.9
Angiotensin 2 receptor blocker 28.8
Diuretics 25.5
Calcium antagonist 21.6
Direct renal inhibitor 1.7
Cholesterol-lowering agents (% of patients)
Statins 68.0
Fibrates 7.4
Antiplatelet agents (%)
Low-dose aspirin 51.1
Clopidogrel 4.7
Adherence
% Patients acknowledging in prior 4 weeks:
Not having taking medication* 35.0 25.8 23.7
Skipping several doses* 21.5 16.1 12.0
Taking medication[ 2 h off schedule^ 25.3 21.8 20.4
Frequency of non-adherence (0–5) (M ± SD)* 0.62 ± 1.0 0.45 ± 0.8 0.37 ± 0.8
VAS rating (0–100) of patient adherence (mean ± SD)
By patient* 84.1 ± 13.5 86.5 ± 11.5 87.2 ± 11.8
972 Diabetes Ther (2019) 10:965–979
of vildagliptin therapy, the mean HbA1c was
8.2 ± 1.3%, and this value decreased signifi-
cantly to 7.4 ± 1.0 and 7.2 ± 1.0% at 105 (visit
2) and 180 days (visit 3) (p\0.0001), respec-
tively. In addition, the proportion of patients
who achieved the recommended glycemic tar-
get (HbA1c\ 7%) increased from 8.6% at initi-
ation of vildagliptin therapy to 35 and 44.6% at
105 and 180 days post-initiation of vildagliptin
(all p\0.0001), respectively (Fig. 2a, c). HbA1c
goal attainment rates were highest among
patients with baseline HbA1c of\ 8.0% at ini-
tiation (Fig. 2e). In parallel, mean FPG levels
decreased from 171.0 ± 53.3 mg/dL at baseline
to 145.3 ± 44.4 and 141.1 ± 44.0 mg/dL at 105
and 180 days, respectively, whereas FPG goal
achievement (FPG\ 126 mg/dl) rate increased
from 14.2% before initiation of vildagliptin
therapy to 37.5 and 42.8% at days 105 and 180
post-initiation of vildagliptin (p\ 0.0001),
respectively (Fig. 2b, d).
As summarized in Table 3, mean BMI, total
cholesterol, LDL-cholesterol, triglycerides, sys-
tolic blood pressure and ALT and AST values all
decreased significantly from baseline to
180 days after initiation of vildagliptin, while
no changes could be observed for HDL and
diastolic blood pressure values. Importantly,
waist circumference, a simple and valid marker
for abdominal obesity, decreased significantly
from baseline to day 180, both in male and
female patients.
Patients who switched to the SPC of vilda-
gliptin and metformin showed no difference in
mean HbA1c at study end compared to those
who remained on vildagliptin and metformin
separately. However, the switched patients
showed greater reductions in mean FPG
(p\ 0.01), and a higher proportion of these
patients achieved the HbA1c (48.5 vs. 42.9%)
(p\ 0.01) and FPG (56.6 vs. 38.8%) (p\ 0.001)
goals despite similar patient-reported adherence
rates. Compared to non-elderly patients,
patients aged[ 65 years evidenced HbA1c and
FPG levels that were between 0.18 and 0.28%
(p\ 0.001), and between 3 and 6 mg/dL
(p\ 0.05), respectively lower. Moreover, com-
pared to patients aged\65 years, those aged C
65 years had consistently higher HbA1c goal
achievement rates at baseline (11.4 vs. 6.5%),
105 days post-initiation of vildagliptin (37.6 vs.
32.9%) and 180 days post-initiation of vilda-
gliptin (47.8 vs. 41.8%; all p\ 0.01), but not
higher FPG goal achievement rates.
Safety
Thirty-seven patients (2.4%) reported a total of
56 AEs, mainly gastro-intestinal AEs (n = 24),
whereas two cases of hypoglycemia were
reported. Seventeen AEs were classified as SAEs,
including three cases of death. Only one SAE,
i.e. anorexia and weight loss, was suspected to
be vildagliptin-related; this SAE was considered
to be a sign of intolerance to vildagliptin, and
treatment was stopped during hospitalization.
AE/SAE rates and liver enzyme levels for elderly
and non-elderly patients were statistically sim-
ilar, as were AE/SAE rates for patients switched
to the SPC vildagliptin/metformin.
Table 2 continued
Treatment patterns and patient adherence Study time points
Baseline 105 – 15 days 180 – 15 days
By physician* 80.5 ± 16.0 84.7 ± 13.9 85.8 ± 13.1
Correlationa 0.76 0.79 0.81
SPC Single pill combination, VAS visual analog scale, GLP-1 glucagon-like peptide-1
*, ^Difference between baseline and visits 2 and 3 was signiﬁcant at *p\ 0.0001 and ^p = 0.0090
a VAS ratings of patient and physician were highly correlated highly at each of the three visits (all p\ 0.0001).
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Fig. 2 Changes in HbA1c and fasting plasma glucose
(FPG) levels. a, b HbA1c (a) and FPG (b) levels during
visit 1 (baseline visit) and follow-up visits 2 and 3 at days
105 and 180 post-initiation of vildagliptin therapy,
respectively. c, d Proportion of patients who reached
glycemic goals of HbA1c\70% (c) and FPG\126 mg/
dL (d) at visits 1, 2 or 3. e Proportion of patients who
reached the glycemic goals of HbA1c\70% at visit 2 or 3
according to HbA1c levels at baseline. Bars and whiskers
represent the mean and standard deviation, respectively.
Asterisks above bars indicate signiﬁcant differences
between study time points at **p\ 0.01; and ***p\ 0.001
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DISCUSSION
The G-FORCE study was conducted to provide
real-world data on the effectiveness and safety
profile of vildagliptin in patients with uncon-
trolled T2DM who had been treated with met-
formin. Data on patient-related factors
determining adherence as well as on physician-
related parameters influencing the general
management of T2DM were also collected. Vil-
dagliptin in a free dose regimen or SPC with
metformin demonstrated significant improve-
ments in glycemic outcomes over a 6-month
period without changes in safety and tolerabil-
ity. In addition, cardiovascular risk factors, such
as BMI, blood pressure and serum lipid levels,
were decreased during the 6-month treatment
period with vildagliptin, suggesting an
improved cardio-metabolic profile. These results
obtained in a real-world setting clearly confirm
the results from randomized clinical trials
(RCTs) and provide important information
regarding the use and effectiveness of vilda-
gliptin in daily clinical practice.
Several RCTs have shown that vildagliptin is
well tolerated and produces clinically mean-
ingful, decreases in HbA1c and FPG in patients
with T2DM inadequately controlled by met-
formin [13, 24]. While RCTs are considered tp
be the gold standard for establishing efficacy,
they have several drawbacks, leading to an
increased interest in real-world data covering
evidence on the relative benefits and harms of
interventions in everyday circumstances [25].
To better understand the real-world clinical
effectiveness and safety of vildagliptin in com-
bination with metformin, we set up this
prospective, observational study.
Treatment with vildagliptin decreased
HbA1c levels by 0.8 and 1.0% after 105 and
Table 3 Evolution of the other clinical outcomes
Clinical parameters Baseline
(mean – SD)
105 – 15 days
(mean – SD)
180 – 15 days
(mean – SD)
pa pb
Body mass index (kg/m2) 30.2 ± 5.6 29.7 ± 5.2 29.2 ± 5.1 \ 0.0001 \ 0.0001
Waist circumference (cm)
male patients
109.2 ± 16.4 108.2 ± 16.3 107.1 ± 15.8 \ 0.0001 0.0011
Waist circumference (cm)
female patients
103.2 ± 16.2 102.0 ± 16.7 101.3 ± 18.5 \ 0.01 ns
Total cholesterol (mg/dL) 193.0 ± 44.4 183.5 ± 38.7 179.9 ± 36.8 \ 0.0001 \ 0.0001
LDL (mg/dL) 107.0 ± 38.2 102.8 ± 35.2 99.0 ± 33.0 0.0003 \ 0.0001
HDL (mg/dL) 50.4 ± 18.9 51.0 ± 18.1 51.2 ± 15.8 ns 0.02
Triglycerides (mg/dL) 180.9 ± 93.8 166.3 ± 82.7 162.9 ± 86.8 \ 0.0001 \ 0.0001
Systolic blood pressure
(mmHg)
135.2 ± 12.8 133.2 ± 10.9 132.3 ± 10.1 \ 0.0001 \ 0.0001
Diastolic blood pressure
(mmHg)
80.7 ± 8.4 80.4 ± 7.2 79.9 ± 7.0 ns \ 0.0001
ALT (U/L) 34.4 ± 27.6 30.7 ± 20.0 30.8 ± 19.8 \ 0.0001 0.0004
AST (U/L) 29.3 ± 20.3 27.4 ± 15.5 27.4 ± 13.8 0.009 ns
ns Non-signiﬁcant, ALT alanine aminotransferase, AST aspartate aminotransferase, HDL high-density lipoprotein, LDL
low-density lipoprotein
a p value vs. baseline
b p value 180 ± 15 days vs. 105 ± 15 days
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180 days of treatment, respectively. These val-
ues are comparable to those values obtained in
RCTs, showing a reduction in HbA1c level of 0.9
and 1.1%, respectively, after 24 and 52 weeks of
treatment with vildagliptin in T2DM patients
already treated with metformin [13, 14, 24]. In
contrast, Ferrannini et al. only showed a 0.44%
reduction in HbA1c levels after 52 weeks of
treatment with vildagliptin [16]; this discrep-
ancy can be explained by the substantial dif-
ference of 0.9% in baseline HbA1c level between
this study and the G-FORCE study (baseline
HbA1c was 7.3% in the study of Ferrannini et al.
and 8.2% in the G-FORCE study). Moreover, our
results are in line with those of a meta-analysis
performed by DeFronzo et al. demonstrating
that higher baseline HbA1c levels are associated
with greater reductions in HbA1c levels, irre-
spective of class or mode of action of the drug
[26]. Also, the HbA1c reduction seen in the
present study confirms results from other
observational studies with vildagliptin showing
reductions in HbA1c level of between 0.8 and
1.19% for baseline HbA1c levels ranging from
7.8 to 8.2% [27–30]. A post-hoc analysis of the
Belgian patients included in the EDGE study, a
1-year observational study with vildagliptin in
T2DM patients with a baseline HbA1C of 8.4%,
revealed a decrease of 0.81% in HbA1c, a value
comparable to that achieved in the present
study [31].
Interestingly, the HbA1c goal achievement
rate of 44.6% at 180 days associated with vil-
dagliptin treatment in the present study was
higher than the 27% obtained in the 24-week
study by Bolli et al., despite similar baseline
HbA1c levels [14]. Bosi et al. demonstrated an
HbA1c goal achievement rate of 54.4% for
patients who started with HbA1c B 7.9% [13],
while the G-FORCE study showed a rate of
74.5% for patients in the same HbA1c category.
Ferrannini et al. reported slightly higher goal
achievement rates of 54% in their 52-week
investigation [16], but this can be explained by
the lower HbA1c baseline value of 7.3% as
compared to 8.2% in the G-FORCE study.
Compared to other real-world observational
studies, we achieved similar goal rates in our
study: for example, in the VILDA [30] and
VICTORY [30] studies, 44.9 and 58.9% of the
patients, respectively, achieved the glycemic
target after 6 months of treatment with vilda-
gliptin, starting from an HbA1c baseline of 7.8
and 8%, respectively.
In our study, glycemic improvement pat-
terns among elderly patients were comparable
to those among non-elderly patients, but the
former achieved lower absolute HbA1c and FPG
levels and a higher percentage achieved the
HbA1c goal with no differences in safety out-
comes. Interestingly, patients switched to the
SPC of vildagliptin and metformin showed no
difference in mean HbA1c at study end com-
pared to those who remained on vildagliptin
and metformin, but the switched patients
showed greater reductions in mean FPG and
higher HbA1c and FPG goal achievement rates
despite similar patient-reported adherence
rates. These results confirm the previous find-
ings of the VICTORY study showing a higher
proportion of patients achieving the glycemic
goal when treated with the SPC of vildaliptin
and metformin as compared to the free regimen
[30]. In short, both vildagliptin and the SPC of
vildagliptin and metformin are effective agents
in the management of diabetes across the age
spectrum, while the SPC of vildagliptin/met-
formin can provide a more convenient alterna-
tive that ensures at least comparable
effectiveness and safety.
Interestingly, not only were improvements
in glycemia and glycemic control achieved, so
were improvements in terms of body weight
and serum lipid levels, suggesting an improved
cardiovascular risk profile. While rather
stable body weight and lipid parameters were
observed in RCTs [13, 16, 24], small improve-
ments in body weight and lipid parameters were
observed in other observational studies with
vildagliptin [27–29]. The G-FORCE study also
showed a mild reduction of systolic blood
pressure of 2 mmHg, but as it has been
demonstrated before that even a small reduc-
tion can have a significant impact on cardio-
vascular risk reduction [32], the combination of
a lower body weight, decreased waist circum-
ference, improved lipid profile and slightly
reduced blood pressure might be an added value
to the glycemic effectiveness of vildagliptin.
976 Diabetes Ther (2019) 10:965–979
Despite the benefits of oral glucose-lowering
agents, our study and other studies have indi-
cated that recommended glycemic goals are
achieved by less than 50% of patients, possibly
due to decreased adherence to therapies [33].
Non-adherence rates in the present study were
substantial and in line with known estimates for
persons living with diabetes [34], but impor-
tantly the percentage of patients not taking
medication, taking it off schedule or skipping
several doses significantly decreased after the
initiation of vildagliptin. Interestingly, patients
switched to the SPC of vildagliptin and met-
formin were similarly non-adherent as those on
the free regimen. However, it should be noted
that the VAS rating, the technique used in this
study to determine medication adherence, is
less accurate than direct measurements such as
pill count and the use of a medication events
monitoring system; consequently, our results
on non-adherence need to be seen as explora-
tory [35]. As has been demonstrated, there is an
inverse relationship between taking a prescribed
oral glucose-lowering agent and HbA1c level,
with each 10% increase in adherence to oral
glucose-lowering agents associated with a 0.1%
decrease in HbA1c [36], while medication non-
adherence also increases the risk for all-cause
hospitalization and mortality [37]. These results
demonstrate that more innovative methods are
needed to assist those patients who fail in their
medication.
CONCLUSION
The data from the present study show that both
the free dose regimen of vildagliptin and met-
formin and the SPC of vildagliptin and met-
formin are effective agents in the glycemic
management of T2DM, while the SPC addi-
tionally leads to an increased proportion of
patients reaching their glycemic goals and lower
FPG levels with comparable effectiveness and
tolerability as the free dose regimen. Impor-
tantly, this observational study shows compa-
rable results in terms of effectiveness and safety
between uncontrolled conditions in real-life
clinical practice and controlled conditions in
RCTs. Nevertheless, despite international
guidelines focusing on an early intensification
of glucose-lowering therapies, this study clearly
revealed a high proportion of suboptimally
treated patients in real life. Therefore, both
endocrinologists and general practitioners
should be more aggressive in the treatment of
T2DM.
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